U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07184385) titled 'A Phase III Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition' on Sept. 17.
Brief Summary: REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Study Start Date: March 31, 2026
Study Type: INTERVENTIONAL
Condition:
Long COVID
Post-COVID-19 Condition
Post-COVID Syndrome
Post-COVID Condition
Intervention:
BIOLOGICAL: REGENECYTE
HPC, Cord Blood
BIOLOGICAL: Placebo
Normal Saline
Recruitment Status: NOT_YET_RECRUITING
Sponsor: StemCyte, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....